Articles on Cancer-Related Topic in http://pharmaceuticalintelligence.com Scientific Journal
Curator: Stephen J Williams, PhD |
|||||
5/5/2014 — OUT OF 1892 articles to date 746 involve the keyword CANCER | |||||
Category |
# posts |
||||
|
|||||
academic publishing | 6 | ||||
advanced drug manufacturing | 21 | ||||
autologous cell therapy | 1 | ||||
automated cell processing | 1 | ||||
Alzheimer’s Disease | 27 | ||||
BioInstrumentation in Experimental Life Sciences Research | 136 | ||||
Biological Networks, Gene Regulation & Evolution | 213 | ||||
Biomarkers & Medical Diagnostics | 226 | ||||
Biomedical Measurement Science | 35 | ||||
BioSimilars | 59 | ||||
Bone Disease and Musculoskeletal Disease | 25 | ||||
Ca | 1 | ||||
Ca++ triggered activation | 5 | ||||
Calcium Signaling | 11 | ||||
Calmodulin Kinase & contraction | 4 | ||||
Cancer | 15 | ||||
Cancer Biology & Innovations in Cancer Therapy | 367 | ||||
Cancer Prevention Research & Programs | 50 | ||||
Cancer Screening | 2 | ||||
Cardiac and Cardiovascular Surgical Proceedures | 25 | ||||
Cardiovascular Pharmacogenetics | 69 | ||||
Cell Biology, Signaling Cell Circuits | 237 | ||||
Cerebrovascular and Neuro&Degenerative Diseases | 18 | ||||
Chemaical Biology and its relations to Metabolic Disease | 138 | ||||
Chemical Genetics | 130 | ||||
Circulating Progenitor Cells | 5 | ||||
Coagulation Therapy and Internal Bleeding | 15 | ||||
Computational Biology/Systems and Bioinformatics | 144 | ||||
Conference Coverage with Social Media | 6 | ||||
Curation | 17 | ||||
cytoskeleton | 12 | ||||
diabetes mellitus | 7 | ||||
diagnostic immunology | 5 | ||||
Disease Biology, Small Molecules in Development of Therapeutic Drugs | 228 | ||||
Drug Delivery Platform Technology | 33 | ||||
Drug Toxicity | 6 | ||||
Ecosystems & Industrial Concentration in the Medical Device Sector | 41 | ||||
FDA Regulatory Affairs | 83 | ||||
Frontiers in Cardiology and Cardiovascular Diseases | 145 | ||||
Genome Biology | 258 | ||||
Genomic Endocrinology, Preimplantation Genetic Diagnosis & Reproductive Genomics | 29 | ||||
Genomic Testing: Methodology for Diagnosis | 149 | ||||
Glycobiology; Biopharmaceutical Production, Pharmacodynamics and Pharmacokinetics | 13 | ||||
Health Economics and Outcomes Research | 135 | ||||
Health Law and Patient Safety | 39 | ||||
HealthCare IT | 28 | ||||
Healthcare Reform | 11 | ||||
hematology | 3 | ||||
Human Immune System in Health and in Disease | 60 | ||||
Human Sensation and Cellular Transduction: Physiology and Therapeutics | 6 | ||||
Imaging-based Cancer Patient Management | 72 | ||||
Immunodiagnostics | 8 | ||||
Infectious Disease & New Antibiotic Targets | 22 | ||||
Infectious disease Immunodiagnostics | 1 | ||||
Innovation in immunology diagnostics | 8 | ||||
Innovations in Neurophysiology & Neuropsychology | 12 | ||||
Intellectual Property, Innovations, Commercialization, Investmetn in technological breakthrough | 6 | ||||
International Global Work in Pharmaceutical | 75 | ||||
Interviews with Scientific Leaders | 88 | ||||
ionic transporters Na | 2 | ||||
K | 1 | ||||
Liver & Digestive Diseases Research | 36 | ||||
Medical & Population Genetics | 104 | ||||
Medical Devices R&D Investment | 60 | ||||
Medical Imaging Technology, Image Processing | 47 | ||||
Metabolomics | 79 | ||||
Molecualr Gentics & Pharmaceutical | 175 | ||||
Na-K transport | 3 | ||||
Na-K-ATPase | 1 | ||||
Nanotechnology for Drug Delivery | 35 | ||||
Nephrology | 1 | ||||
Nephrology & Regenerative Medicine | 1 | ||||
Neurodegenerative diseases | 1 | ||||
Nitric Oxide in Health and Disease | 40 | ||||
Nutrigenomics | 27 | ||||
Nutrition | 45 | ||||
Open Access Journals | 3 | ||||
Pain, Etiology, Genetics & Innovations in Treatment | 3 | ||||
Patient Experience: Personal Memories of Invasive Medical Intervention | 4 | ||||
Personalized Medicine & Genomic Research | 259 | ||||
Pharmaceutical Analytics | 55 | ||||
Pharmaceutical Industry Compettive Intelligence | 62 | ||||
Pharmaceutical R&D Investment | 104 | ||||
Pharmacogenomics | 63 | ||||
Population Health Management, Genetics & Pharmaceutical | 195 | ||||
Population Health Management, Nutrition & Phytochemistry | 59 | ||||
Proteomics | 63 | ||||
regenerative biology and medicine | 8 | ||||
Regulated Clinical Trials; Design, Methods, Components and IRB related issues | 99 | ||||
Reproductive Biology & Bio Instrumentation | 14 | ||||
Scientific & Biotech Conferences: Press Coverage | 2 | ||||
Scientist: Career Considerations | 60 | ||||
Signaling | 8 | ||||
Statistical Methods for Reseach Evaluation | 47 | ||||
Stem Cells for Regeneration | 51 | ||||
Systemic Inflammatory Response Related Disorders | 49 | ||||
Technology Transfers Biotech and Pharmaceutical | 162 | ||||
Translational Science | 34 | ||||
Uncategorized | 74 | ||||
water transporters | 2 |
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.